Literature DB >> 7963543

Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.

W P Arend1, M Malyak, M F Smith, T D Whisenand, J L Slack, J E Sims, J G Giri, S K Dower.   

Abstract

These studies have examined the binding of the three IL-1 ligands, IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist (IL-1 ra), to soluble forms of types I and II IL-1Rs (sIL-1RI and sIL-1RII). This interaction was measured in direct binding experiments, in which the ligands bound to immobilized sIL-1R, and in inhibition experiments, in which sIL-1R in solution inhibited the binding of IL-1 ligands to immobilized sIL-1R. In addition, the effects of sIL-1R on the detection of IL-1 ligands by ELISA were examined. Finally, levels of sIL-1R in synovial fluid samples were determined, and their effects on measurement of IL-1 in these samples were estimated. IL-1 beta bound more avidly to sIL-1RII than IL-1 alpha or IL-1ra, primarily because of a slow dissociation rate. In contrast, IL-1 ra bound more avidly than IL-1 alpha or IL-1 beta to sIL-1RI, again because of a slow dissociation rate. sIL-1RII and sIL-1RI inhibited the detection of IL-1 beta and IL-1ra, respectively, by ELISA. Low levels of sIL-1RI (approximately 1.0-2.5 ng/ml) were present in all synovial fluids, irrespective of the degree of inflammation, and were correlated inversely with the levels of measured IL-1ra. In contrast, higher levels of sIL-1RII (approximately 10-20 ng/ml) were found in inflammatory synovial fluids and were not correlated with IL-1ra levels. IL-1 beta could not be detected in any synovial fluid. These results suggest that some IL-1 beta and IL-1ra may be bound in vivo to sIL-1RII and sIL-1RI, respectively, leading to underestimations of cytokine concentrations in body fluids when measured by ELISA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963543

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.

Authors:  S Youssef; G Maor; G Wildbaum; N Grabie; A Gour-Lavie; N Karin
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  The use of anakinra in juvenile arthritis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

4.  Design of a superior cytokine antagonist for topical ophthalmic use.

Authors:  Jinzhao Hou; Sharon A Townson; Joseph T Kovalchin; Allyson Masci; Olga Kiner; Yanqun Shu; Bracken M King; Emily Schirmer; Kathryn Golden; Christoph Thomas; K Christopher Garcia; Gregory Zarbis-Papastoitsis; Eric S Furfine; Thomas M Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

5.  Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system.

Authors:  P Aukrust; F Müller; M Svenson; I Nordøy; K Bendtzen; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors.

Authors:  Krista O'Shaughnessey; Andrea Matuska; Jacy Hoeppner; Jack Farr; Mark Klaassen; Christopher Kaeding; Christian Lattermann; William King; Jennifer Woodell-May
Journal:  J Orthop Res       Date:  2014-07-01       Impact factor: 3.494

Review 7.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

8.  Allosteric switching of agonist/antagonist activity by a single point mutation in the interluekin-1 receptor antagonist, IL-1Ra.

Authors:  Kendra L Hailey; Dominique T Capraro; Sulyman Barkho; Patricia A Jennings
Journal:  J Mol Biol       Date:  2013-03-15       Impact factor: 5.469

9.  Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

Authors:  Marianne Böni-Schnetzler; Jeffrey Thorne; Géraldine Parnaud; Lorella Marselli; Jan A Ehses; Julie Kerr-Conte; Francois Pattou; Philippe A Halban; Gordon C Weir; Marc Y Donath
Journal:  J Clin Endocrinol Metab       Date:  2008-07-29       Impact factor: 5.958

10.  Expression and function of TNF and IL-1 receptors on human regulatory T cells.

Authors:  Frances Mercer; Lina Kozhaya; Derya Unutmaz
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.